Outcomes of patients with MC. One other patient (not included in Figure 1 because of residual ALL on day +30) had 90% donor chimerism by DNA analysis (VNTR) and 100% donor chimerism by cytogenetic analysis. After discontinuation of immunosuppression, this patient had 95% donor chimerism and no evidence of ALL. Thus, the patient was considered evaluable for engraftment on day +100 (but not day +30). A-CR, patients alive in complete remission; A-R, alive in relape; D-R, death due to relapse; D-TRM, death due to transplant-related mortality; f/u, follow-up. *Patient who remained MC on day +100 and then experienced secondary graft failure after day +100. This patient had CML and underwent a sex-mismatched transplant. The routine cytogentics showed 46 XX and the fluorescent in situ hybridization (FISH) and reverse transcriptase-polymerase chain reaction (RT-PCR) for bcr/abl were negative following the secondary graft failure.